Table 3.
Species | Tested method | HSV-1 | HSV-2 | EBV | CMV |
Gorilla [5] | ELISA, Immunoblot | 49/53(92.5%) | 4/53 (7.5%) | - | - |
Chimpanzee [5] | ELISA, Immunoblot | 2/38 (5.3%) | 5/38(13.2%) | - | - |
Orangutan [5] | ELISA, Immunoblot | 5/70 (7.1%) | - | - | - |
Gibbon [5] | ELISA, Immunoblot | 8/24 (33.3%) | - | - | - |
Chimpanzee [5] | Complement-Fixation | - | - | 10/10 (100%) | - |
Baboon [9] | Complement-Fixation | - | - | 2/10 (20%) | - |
Cynomolgous [9] | Complement-Fixation | - | - | 10/10 (100%) | - |
Rhesus [9] | Complement-Fixation | - | - | 6/9 (66.7%) | - |
African Green [9] | Complement-Fixation | - | - | 9/10 (90%) | - |
Rhesus [14] | Serum neutralization | 67/164 (40.9%) | - | - | - |
Dot-immunobinding | 77/164 (47.0%) | - | - | - | |
Chimpanzee [14] | Fluorescent antibody | - | - | 2/8 (25%) | |
Dot-immunobinding | - | - | - | 5/8 (62.5%) | |
Gibbon (our study) | ELISA | 22/78 (28.2%) | 22/78 (28.2%) | 11/78 (14.1%) | 14/78 (17.9%) |